Orexo has developed from being an R&D stage company to becoming a profitable fully integrated specialty pharmaceutical company with its own commercial business in the US. From a strong operational and financial platform, Orexo is aiming to become a leader in the field of addiction. To achieve this, the commercial business will be broadened through business development, M&A and launch of proprietary pharmaceuticals and digital therapies.
Objectives and strategies 2020 and onwards
1. Broaden the portfolio of commercial products to be promoted by our US organization
2. Maintain Zubsolv® profit contribution in 2020 and ensure it is sustainable and growing over time
3. Establish a new revenue generating business area within Digital Therapeutics and launch the first new product in 2020
4. Launch a new product from the pharmaceutical pipeline within the next two years
